Patient Stratification and Treatment Response Prediction in Neuropharmacotherapy Using Hybrid Positron Emmission Tomography/Magnetic Resconance Imaging (PET/MR)

Major Depressive Disorder Clinical Trial

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02711215
• Other study ID #: 1.6_20180316
• Status: Active, not recruiting
• Phase: Phase 4
• Start date: May 2015
• Est. completion date: January 2020

Study information

• Verified date: August 2019
• Source: Medical University of Vienna
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Selective serotonin reuptake inhibitors (SSRIs) raise serotonin (5-HT) in the synaptic cleft and are the current first line of pharmacological antidepressive treatment. Yet, there is a missing link between this first molecular step in their mechanism of action and observed clinical improvement. We have determined to establish a framework combining genuine molecular and functional imaging, i.e. hybrid pharmaco-PET/MR imaging, of the human serotonergic system in order to predict antidepressant treatment response.

Objectives:

1. To predict antidepressant treatment response from data obtained using hybrid PET/MR with acute pharmacological challenge.

2. To discriminate healthy from depressed subjects using this paradigm.

3. To establish models connecting regional changes in occupancy of serotonin transporters (5-HTT) following citalopram infusion, with changes in brain activation and connectivity of major resting-state hub networks.

Design: Randomized, double-blind, placebo-controlled, cross-over mono-center study.

Materials and methods:

40 major depressed (MDD) and 40 healthy subjects will undergo 2 PET/MR scans on a 3T SIEMENS mMR Biograph scanner: 1. challenge with citalopram 8mg 2. placebo (saline). After structural imaging, functional MRI will be continuously acquired. [11C]DASB will be applied using a bolus + constant infusion paradigm to probe 5-HTT binding potentials and monitor 5-HTT occupancy with drug challenge, applied after 70min, in a single session. Scanning will be terminated 80min after challenge. MDD patients will receive subsequent escitalopram treatment with repeated evaluation of response for 3 months.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 80
• Est. completion date: January 2020
• Est. primary completion date: January 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• General health based on medical history, physical examination and structured clinical interview for DSM-IV (SCID)

• HAM-D=18 (patients)

• Willingness and competence to sign the informed consent form

• Age 18 to 55 years

Exclusion Criteria:

• Any medical, psychiatric or neurological illness (other than MDD)

• Current or former psychopharmacological treatment

• Current or former substance abuse

• Pregnancy

• Any implant or stainless steel graft or any other contraindications for MRI

• Failure to comply with the study protocol or to follow the instructions of the investigating team

• Participation in studies involving radiation exposure in the past 10 years.

• Body mass index <17 or >30

Related Conditions & MeSH terms

• Depressive Disorder
• Depressive Disorder, Major
• Major Depressive Disorder

Intervention

Diagnostic Test:
• PET/MR [11C]DASB
2 PET/MR scans will be performed (placebo/citalopram - double-blind randomized cross-over)

Drug:
• Citalopram
8mg citalopram or placebo (saline) will be applied during PET/MR measurements in a double-blind randomized cross-over design
• Escitalopram (Mirtazapine/Duloxetine/Venlafaxine)
After completion of imaging procedures, patients will receive treatment with escitalopram 10-20mg. In case of non-response, after 6 weeks, treatment will be switched to either Mirtazapine, Duloxetine or Venlafaxine
• Placebo
8mg citalopram or placebo (saline) will be applied during PET/MR measurements in a double-blind randomized cross-over design

Locations

Country	Name	City	State
Austria	Department of Psychiatry and Psychotherapy, Medical University of Vienna	Vienna

Sponsors (1)

Lead Sponsor	Collaborator
Medical University of Vienna

Country where clinical trial is conducted

Austria, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Hamilton Depression Scale (HDRS)		12 weeks